These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 37392610)

  • 41. Diverse Genetic Background of Multidrug-Resistant Pseudomonas aeruginosa from Mainland China, and Emergence of an Extensively Drug-Resistant ST292 Clone in Kunming.
    Fan X; Wu Y; Xiao M; Xu ZP; Kudinha T; Bazaj A; Kong F; Xu YC
    Sci Rep; 2016 May; 6():26522. PubMed ID: 27198004
    [TBL] [Abstract][Full Text] [Related]  

  • 42. β-lactamase-mediated resistance in MDR-Pseudomonas aeruginosa from Qatar.
    Sid Ahmed MA; Khan FA; Sultan AA; Söderquist B; Ibrahim EB; Jass J; Omrani AS
    Antimicrob Resist Infect Control; 2020 Nov; 9(1):170. PubMed ID: 33131487
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of antimicrobial resistance in Klebsiella species isolated from chicken broilers.
    Wu H; Wang M; Liu Y; Wang X; Wang Y; Lu J; Xu H
    Int J Food Microbiol; 2016 Sep; 232():95-102. PubMed ID: 27289192
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characteristics of multiresistant Pseudomonas aeruginosa isolates from burn patients in Iran.
    Abednezhad A; Bakhshi B; Moghadam NA; Faraji N; Derakhshan-Nezhad E; Mohammadi Barzelighi H
    Acta Microbiol Immunol Hung; 2023 Mar; 70(1):29-37. PubMed ID: 36689252
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021.
    Lee YL; Ko WC; Hsueh PR
    Int J Antimicrob Agents; 2023 Aug; 62(2):106867. PubMed ID: 37244423
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epidemiological and Genetic Characteristics of Clinical Carbapenem-Resistant
    Zhao Y; Chen D; Chen K; Xie M; Guo J; Chan EWC; Xie L; Wang J; Chen E; Chen S; Chen W; Jelsbak L
    Microbiol Spectr; 2023 Jun; 11(3):e0426122. PubMed ID: 37078855
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Detection of synergistic antimicrobial resistance mechanisms in clinical isolates of Pseudomonas aeruginosa from post-operative wound infections.
    Awan AB; Yan A; Sarwar Y; Schierack P; Ali A
    Appl Microbiol Biotechnol; 2021 Dec; 105(24):9321-9332. PubMed ID: 34797390
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Description of IMP-31, a novel metallo-β-lactamase found in an ST235 Pseudomonas aeruginosa strain in Western Germany.
    Pfennigwerth N; Geis G; Gatermann SG; Kaase M
    J Antimicrob Chemother; 2015 Jul; 70(7):1973-80. PubMed ID: 25835992
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antimicrobial resistance and resistance genes in Salmonella strains isolated from broiler chickens along the slaughtering process in China.
    Zhu Y; Lai H; Zou L; Yin S; Wang C; Han X; Xia X; Hu K; He L; Zhou K; Chen S; Ao X; Liu S
    Int J Food Microbiol; 2017 Oct; 259():43-51. PubMed ID: 28800411
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genomic and phylogenetic analysis of a multidrug-resistant Pseudomonas aeruginosa ST463 strain co-carrying bla
    Sun L; Guo H; Chen Y; He F; Xu J
    J Glob Antimicrob Resist; 2023 Jun; 33():301-303. PubMed ID: 37116612
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antimicrobial susceptibility study and molecular epidemiology of ceftazidime/avibactam against
    Hu Y; Chen J; Huang L; Liu C; Zhou H; Zhang R
    J Med Microbiol; 2023 Feb; 72(2):. PubMed ID: 36753319
    [No Abstract]   [Full Text] [Related]  

  • 52. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
    Ruedas-López A; Alonso-García I; Lasarte-Monterrubio C; Guijarro-Sánchez P; Gato E; Vázquez-Ucha JC; Vallejo JA; Fraile-Ribot PA; Fernández-Pérez B; Velasco D; Gutiérrez-Urbón JM; Oviaño M; Beceiro A; González-Bello C; Oliver A; Arca-Suárez J; Bou G
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0206721. PubMed ID: 34930034
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emergence and Spread of Epidemic Multidrug-Resistant Pseudomonas aeruginosa.
    Miyoshi-Akiyama T; Tada T; Ohmagari N; Viet Hung N; Tharavichitkul P; Pokhrel BM; Gniadkowski M; Shimojima M; Kirikae T
    Genome Biol Evol; 2017 Dec; 9(12):3238-3245. PubMed ID: 29202180
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PME and Other ESBL-Positive Multiresistant Pseudomonas aeruginosa Isolated from Hospitalized Patients in the Region of Kurdistan, Iraq.
    van Burgh S; Maghdid DM; Ganjo AR; Mansoor IY; Kok DJ; Fatah MH; Alnakshabandi AA; Asad D; Hammerum AM; Ng K; Klaassen C; Goessens WHF
    Microb Drug Resist; 2019; 25(1):32-38. PubMed ID: 30067166
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Temporo-spatial variations in resistance determinants and clonality of Acinetobacter baumannii and Pseudomonas aeruginosa strains from Romanian hospitals and wastewaters.
    Gheorghe-Barbu I; Barbu IC; Popa LI; Pîrcălăbioru GG; Popa M; Măruțescu L; Niță-Lazar M; Banciu A; Stoica C; Gheorghe Ș; Lucaciu I; Săndulescu O; Paraschiv S; Surleac M; Talapan D; Muntean AA; Preda M; Muntean MM; Dragomirescu CC; Popa MI; Oțelea D; Chifiriuc MC
    Antimicrob Resist Infect Control; 2022 Sep; 11(1):115. PubMed ID: 36104761
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased prevalence and clonal dissemination of multidrug-resistant Pseudomonas aeruginosa with the blaIMP-1 gene cassette in Hiroshima.
    Kouda S; Ohara M; Onodera M; Fujiue Y; Sasaki M; Kohara T; Kashiyama S; Hayashida S; Harino T; Tsuji T; Itaha H; Gotoh N; Matsubara A; Usui T; Sugai M
    J Antimicrob Chemother; 2009 Jul; 64(1):46-51. PubMed ID: 19398456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of methods to analyse susceptibility of German MDR/XDR Pseudomonas aeruginosa to ceftazidime/avibactam.
    Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA
    Int J Antimicrob Agents; 2019 Aug; 54(2):255-260. PubMed ID: 31071465
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Investigation of beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa isolated from non-tertiary care hospitals in Korea.
    Suk SE; Yoo JS; Lee JK; Lee KM; Chung GT; Shin ES; Han SY; Lee SH; Kim J; Lee YS
    J Microbiol Biotechnol; 2007 Oct; 17(10):1733-7. PubMed ID: 18156795
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.
    Fraile-Ribot PA; Cabot G; Mulet X; Periañez L; Martín-Pena ML; Juan C; Pérez JL; Oliver A
    J Antimicrob Chemother; 2018 Mar; 73(3):658-663. PubMed ID: 29149337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
    Juan C; Zamorano L; Pérez JL; Ge Y; Oliver A; ;
    Antimicrob Agents Chemother; 2010 Feb; 54(2):846-51. PubMed ID: 19933793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.